Clinical Trial Update: Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

View source ↗

Summary

The compassionate use program for trametinib and dabrafenib in BRAF-mutant metastatic melanoma has ended and is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Status: NO_LONGER_AVAILABLE